Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma

Background: The SPOTLIGHT trial demonstrated that zolbetuximab plus mFOLFOX6 (ZOL-FO) as a first-line regimen compared with placebo plus mFOLFOX6 (PLB-FO) conferred clinical benefits to patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yufan, You, Maojin, Wu, Qundan, Chen, Ruijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500349/
https://www.ncbi.nlm.nih.gov/pubmed/37719841
http://dx.doi.org/10.3389/fphar.2023.1238009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500349/
https://www.ncbi.nlm.nih.gov/pubmed/37719841
http://dx.doi.org/10.3389/fphar.2023.1238009

Ejemplares similares